According to the GlaxoSmithKline, the results of a Phase III study demonstrated that pazopanib significantly reduced the risk of tumor progression or death by 54 percent compared to placebo.
Pazopanib is an oral medicine that prevents the growth of new blood vessels to tumors.
These results were presented at the annual American Society for Clinical Oncology(ASCO) meeting in Orlando, Florida. <헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지